The use of green tea polyphenols for treating residual albuminuria in diabetic nephropathy: A double-blind randomised clinical trial

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Borges, Cynthia M ^a   Papadimitriou, Alexandros ^a   Duarte, Diego A ^a   Lopes De Faria, Jacqueline M ^a   Lopes De Faria, José B ^a  

^a Faculty of Medical Sciences   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHIN; EPIGALLOCATECHIN GALLATE; POLYPHENOL;

AGED; ALBUMINURIA; ANALOGS AND DERIVATIVES; APOPTOSIS; CELL CULTURE; CHEMISTRY; CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PEA; PHASE 2 CLINICAL TRIAL; PODOCYTE; RANDOMIZED CONTROLLED TRIAL;

AGED; ALBUMINURIA; APOPTOSIS; CATECHIN; CELLS, CULTURED; DIABETIC NEPHROPATHIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PEAS; PODOCYTES; POLYPHENOLS;

EID: 84975513333     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep28282     Document Type: Article

References (30)

1. Gaede, P., Vedel, P., Parving, H. H., Pedersen, O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 353, 617-622 (1999).
2. Tuttle, K. R. et al. Diabetic kidney disease: a report from ADA Consensus Conference. Diabetes Care 37, 2864-2883 (2014).
3. De Zeeuw, D. et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 110, 921-927 (2004).
4. Holtkamp, F. A. et al. Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy. Eur. Heart J. 32, 1493-1499 (2011).
5. Ninomiya, T. et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J. Am. Soc. Nephrol. 20, 1813-1821 (2009).
6. Schmeider, R. E. et al. Mortality and morbidity in relation to changes in albuminuria, glucose status and systolic blood pressure. Diabetologia 57, 2019-2029 (2014).
7. Bakris, G. L. Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitus. Mayo Clin. Proc. 86, 444-456 (2011).
8. Yamout, H., Lazich, I., Bakris, G. L. Blood pressure, hypertension, RAAS blockade, and drug therapy in diabetic kidney disease. Adv. Chronic. Kidney Dis. 21, 281-286 (2014).
9. De Zeeuw, D. et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL. Kidney Int. 65, 2309-2320 (2004).
10. Ribaldo, P. D. B. et al. Green tea (Camellia sinensis) attenuates nephropathy by downregulating Nox4 NADPH oxidase in diabetic spontaneously hypertensive rats. J. Nutr. 139, 96-100 (2009).
11. Faria, A. M., Papadimitriou, A., Silva, K. C., Lopes de Faria, J. M., Lopes de Faria, J. B. Uncoupling endothelial nitric oxide synthase is ameliorated by green tea in experimental diabetes by re-establishing tetrahydrobiopterin levels. Diabetes 61, 1838-1847 (2012).
12. Peixoto, E. B. et al. Reduced LRP6 expression and increase in the interaction of GSK3 with p53 contribute to podocyte apoptosis in diabetes mellitus and are prevented by green tea. J. Nutr. Biochem. 4, 416-430 (2015).
13. Peng, A. et al. The green tea polyphenol ( )-epigallocatechin-3-gallate ameliorates experimental immune-mediated glomerulonephritis. Kidney Int. 80, 601-611 (2011).
14. Kato, H. et al. Wnt/b-catenin pathway in podocytes integrates cell adhesion, differentiation, and survival. J. Biol. Chem. 286, 26003-26015 (2011).
15. Ras, R. T., Zock, P. L., Draijer, R. Tea consumption enhances endothelial-dependent vasodilation: a meta-analysis. PLoS One 6, e16974 (2011).
16. Wu, A. H. et al. Effect of 2-month controlled green tea intervention on lipoprotein cholesterol, glucose, and hormone levels in healthy postmenopausal women. Cancer Prev. Res. 5, 393-402 (2012).
17. Navarro-González, J. F., Mora-Fernández, C. The role of inflammatory cytokines in diabetic nephropathy. J. Am. Soc. Nephrol. 19, 433-442 (2008).
18. Garcia-Martín, A. et al. Relationship of Dickkopf1 (DKK1) with cardiovascular disease and bone metabolism in Caucasian type 2 diabetes mellitus. PLoS One 9, e111703 (2014).
19. Lattanzio, S. et al. Circulating dickkopf-1 in diabetes mellitus: association with platelet activation and effects of improved metabolic control and low-dose aspirin. J. Am. Heart Assoc. 3, 3-11 (2014).
20. Bafico, A., Liu, G., Yaniv, A., Gazit, A., Aaronson, S. A. Novel mechanism of Wnt signalling inhibition mediated by Dickkopf-1 interaction with LRP-6. Nat. Cell Biol. 3, 683-686 (2001).
21. Li, Z., Xu, J., Xu, P., Liu, S., Yang, Z. Wnt-catenin signalling pathway mediates high glucose induced cell injury through activation of TRPC6 in podocytes. Cell Prolif. 46, 76-85 (2013).
22. Cohen, P., Frame, S. The renaissance of GSK3. Mol. Cell Biol. 2, 769-76 (2001).
23. Merscher-Gomez, S. et al. Cyclodextrin protects podocytes in diabetic kidney disease. Diabetes 62, 3817-3827 (2013).
24. Saleem, M. A. et al. A conditionally immortalized human podocyte cell line demonstrating nephrin and podocin expression. J. Am. Soc. Nephrol. 13, 630-638 (2002).
25. Chow, H. H. et al. Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of polyphenon E in healthy individuals. Clin. Cancer Res. 12, 4627-4633 (2005).
26. Papadimitriou, A., King, A. J., Jones, P. M., Persaud, S. J. Anti-apoptotic effects of arachidonic acid and prostaglandin E2 in pancreatic beta-cells. Cell Physiol. Biochem. 20, 607-616 (2007).
27. Fang, L. et al. Autophagy attenuates diabetic glomerular damage through protection of hyperglycemia-induced podocyte injury. PLoS One 8, e60546 (2013).
28. Schjoedt, K. J. et al. Benefical impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int. 70, 536-542 (2006).
29. Fleiss, J. L., Levin, B., Paik, M. C. Statistical Methods for Rates and Proportions. 2nd ed. (John Wiley & Sons, 1981).
30. Hulley, S. B., Cummings, S. R., Browner, W. S., Grady, D. G., Newman, T. B. Designing Clinical Research. 4th ed. (Williams & Wilkins, 2013).